Wegovy 1.5mg Tablets – Semaglutide Weight Management

Wegovy 1.5mg Tablets – Semaglutide Weight Management

Wegovy 1.5mg Tablets contain semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist authorised in the UK for weight management in eligible adults. The medicine is used alongside a reduced-calorie diet and increased physical activity as part of a comprehensive approach to weight management.

Wegovy 1.5mg Tablets are an oral formulation of semaglutide manufactured by Novo Nordisk. The product shown on this page is the 1.5mg tablet presentation supplied in packs of 30 tablets. Current UK product information confirms that Wegovy tablets are available in several strengths, including 1.5mg, 4mg, 9mg and 25mg.

What are Wegovy 1.5mg Tablets?

Wegovy 1.5mg Tablets contain semaglutide, an active substance that works in a similar way to the naturally occurring hormone GLP-1. Semaglutide acts on receptors involved in appetite regulation and can help people feel fuller, experience less hunger and reduce food cravings.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved the Wegovy tablet for weight loss and weight management in June 2026. The authorised indication applies to eligible adults with obesity or overweight accompanied by at least one weight-related health condition.

For official information, you can review the UK MHRA guidance on the Wegovy tablet.

Wegovy 1.5mg Tablets and Semaglutide

Semaglutide is the active ingredient in Wegovy. As a GLP-1 receptor agonist, it helps regulate appetite and food intake. Wegovy treatment is intended to be used together with lifestyle measures rather than as a replacement for a balanced diet or physical activity.

The 1.5mg tablet is the starting strength described in the current UK Patient Information Leaflet. Treatment is prescribed and monitored by a healthcare professional, who determines whether the medicine is appropriate and how treatment should progress.

Patients should never change their dose or treatment schedule without speaking to their prescribing healthcare professional.

What is Wegovy 1.5mg used for?

Wegovy tablets are authorised for weight management in eligible adults. According to the current UK Summary of Product Characteristics, treatment is indicated alongside a reduced-calorie diet and increased physical activity for adults with an initial body mass index (BMI) of 30 kg/m² or greater, or adults with a BMI from 27 kg/m² to below 30 kg/m² who have at least one weight-related comorbidity.

Eligibility for treatment should be assessed by an appropriate healthcare professional. A prescription should not be based solely on a person’s desired weight or appearance.

How do Wegovy tablets work?

Wegovy contains semaglutide, which acts on GLP-1 receptors involved in appetite regulation. This can increase feelings of fullness and reduce hunger and food cravings. By supporting reduced food intake alongside dietary and physical-activity measures, semaglutide can contribute to weight reduction and weight maintenance in eligible patients.

Individual results vary, and treatment should be monitored by a healthcare professional.

Wegovy 1.5mg Tablets – How to Take

Wegovy tablets are taken orally. The official UK Patient Information Leaflet instructs patients to take the tablet on an empty stomach following a fasting period of at least 8 hours, swallow it whole with a sip of water of up to 120 mL, and wait at least 30 minutes before eating, drinking or taking other oral medicines.

The current treatment schedule described in the UK leaflet begins with one 1.5mg tablet once daily for the first month. The dose is then gradually increased under medical supervision. Patients should follow the exact treatment instructions given by their prescriber and should not take two tablets to achieve a higher dose.

For complete administration instructions, read the official Wegovy 1.5mg Tablets Patient Information Leaflet.

Wegovy Tablets 30 Pack

The product shown on this page is the 1.5mg tablet presentation in a 30-tablet pack. The current UK product information confirms that Wegovy 1.5mg tablets are supplied in aluminium/aluminium blister cards and are available in pack sizes including 10, 30 and 90 tablets, although not every pack size may be marketed at all times.

Prescription Requirements in the UK

Wegovy is a prescription-only medicine. Treatment should be supplied following an appropriate assessment by a qualified healthcare professional.

Before prescribing semaglutide, a healthcare professional can assess the patient’s medical history, current medicines, eligibility, potential contraindications and other factors that may affect treatment.

Patients should not obtain Wegovy from unregulated sellers or websites that supply prescription medicines without the appropriate prescribing process.

Wegovy and Weight Management

Wegovy is specifically authorised for weight management in eligible adults. It should be used alongside a reduced-calorie diet and increased physical activity.

Weight management treatment is most effective when incorporated into an appropriate long-term healthcare plan. Patients should follow the dietary, physical-activity and treatment recommendations provided by their healthcare professional.

You can also explore our Pharmacy Store Online for additional healthcare information and relevant pharmacy resources.

Possible Side Effects

Like all medicines, Wegovy can cause side effects, although not everyone experiences them. Common side effects associated with semaglutide include gastrointestinal symptoms such as nausea, diarrhoea, constipation and vomiting.

Patients should read the complete Patient Information Leaflet before starting treatment and speak with their doctor, pharmacist or nurse if they experience side effects or have concerns about their medicine.

Severe or persistent symptoms should receive appropriate medical attention. Patients should seek urgent medical advice for serious or unexpected symptoms.

Important Safety Information

Wegovy is not suitable for everyone. Patients should tell their healthcare professional about their medical history, existing health conditions, allergies and all medicines they currently take.

People with type 2 diabetes should inform their doctor before starting Wegovy because diabetes medicines may require adjustment to reduce the risk of low blood sugar.

Patients should not combine Wegovy with other semaglutide-containing medicines or other GLP-1 receptor agonists unless specifically instructed by an appropriate healthcare professional.

Do not change the prescribed dose, take additional tablets or alter the treatment schedule without professional advice.

Wegovy Storage Information

The current UK Patient Information Leaflet states that Wegovy tablets should be kept out of the sight and reach of children and stored in the original package to protect the medicine from light and moisture. The product does not require special temperature storage conditions according to the current leaflet.

Do not use the medicine after the expiry date printed on the packaging. Unused medicines should be disposed of appropriately. Ask a pharmacist how to dispose of medicines you no longer need.

Wegovy 1.5mg Tablets vs Other Semaglutide Medicines

Several medicines contain semaglutide, but they do not all have the same authorised indications, formulations or dosing schedules. Wegovy tablets are specifically authorised for weight management in eligible adults, while other semaglutide medicines may have different licensed uses.

Patients should not assume that different semaglutide products are interchangeable. The appropriate medicine should be selected by a qualified healthcare professional based on the patient’s circumstances and the authorised indication of the specific product.

Why Choose an Authorised Medicine?

Using an authorised medicine helps ensure that the product has undergone the relevant regulatory assessment for quality, safety and effectiveness. The MHRA advises patients to obtain prescription medicines through legitimate healthcare and pharmacy channels.

Patients should be cautious of websites, social-media sellers or other sources offering prescription medicines without appropriate healthcare assessment.

Final Information

Wegovy 1.5mg Tablets are oral semaglutide tablets authorised in the UK for weight management in eligible adults. They contain 1.5mg of semaglutide per tablet and are supplied in packs that can include 30 tablets.

Wegovy treatment should be used as prescribed and alongside appropriate dietary and physical-activity measures. Always follow the instructions provided by your healthcare professional and read the official Patient Information Leaflet before starting treatment.

If you have questions about whether Wegovy is suitable for you, speak with a doctor, pharmacist or other qualified healthcare professional.